La Apple Watch import ban The US market has taken a new turn following the latest development in the American courts. Although the dispute is being fought on the other side of the Atlantic, what happens there could shape the future of the global smartwatch market, with indirect repercussions for users and distributors in Europe as well.
At the heart of the conflict is the technology to measure blood oxygen levels integrated into certain Apple Watch models. A US trade court has preliminarily concluded that current versions of the watch no longer infringe on patents held by the medical company Masimo, complicating the possibility of imposing a new ban on its entry into the country.
What has the US justice system decided now about the Apple Watch?
The starting point is a preliminary ruling of a U.S. commercial courtwhich has determined that the Apple Watch models currently marketed by Apple do not infringe Masimo's patents related to the pulse oximetry, the technology that allows estimating the level of oxygen in the blood.
This decision halts, at least for the moment, Massimo's intention to achieve a new Apple Watch import ban in the United States. The medical monitoring company had requested the reinstatement of the ban, arguing that Apple continued to infringe its intellectual property rights despite the changes made to the device.
The commercial court's ruling is based on the prior work of a judge of the International Trade Commission (ITC)The court had already ruled that the redesigned watches do not infringe on the disputed patents. According to this ruling, the adjustments Apple made to the hardware and software are sufficient to circumvent the injunction issued in 2023.
However, the ball isn't entirely in Apple's court: The entire ITC still needs to review and decide whether to uphold the judge's assessment. Until the commission confirms or corrects the decision, the legal situation remains open and subject to further changes.
In parallel, the Court of Appeals for the Federal Circuit The United States has upheld its 2023 ruling that originally prohibited the importation of models deemed to be in violation. In other words, the ban on older versions remains in place, but the current situation regarding modified units already entering the country is accepted.
How the Apple Watch import ban began
To understand the scope of this decision, we must go back to the blocking order issued by the ITC in December 2023At that time, the Commission concluded that the Apple Watch Series 9 and Ultra 2 infringed several of Masimo's patents on blood oxygen measurement technologies, which are fundamental to the watch's health functions.
Masimo, based in Irvine, California, accused Apple of hire some of their staff to appropriate key developments in pulse oximetry, a type of sensor that allows estimation of oxygen saturation levels without the need for a traditional blood test. These accusations led to a patent battle on several fronts and in different US courts.
As a result of the ITC's decision, Apple was forced to interrupt the import and sale In the United States, the affected models included the original implementation of the blood oxygen function. This ban generated uncertainty in the market and forced the company to act quickly.
The ban focused on those specific models and that specific version of the health technology, so the Cupertino company opted for a pragmatic strategy: changing the product to no longer fit the definition that the ITC had considered infringing.
The changes Apple introduced to the Apple Watch to circumvent the ban
Following the block, Apple proceeded to redesign the function of oxygen in the blood in their watches, both at the software level and in the way the data is presented to the user. The objective was clear: to continue offering health metrics without infringing on the patents that the ITC had deemed to be violated.
One of the most significant changes is that, in the updated models, The oxygen sensor information is no longer displayed directly on the watch. in the same way as before. Now, the data is visualized in associated devices, such as the iPhone, which act as the main screen for that specific measurement.
In the previous version, the Apple Watch allowed users to check their blood oxygen saturation directly on their wrist, something the ITC directly linked to the use of technology patented by Masimo. The new configuration aims to differentiate itself from that approach and limit potential technical overlap.
These changes were submitted for review by the U.S. Customs and Border ProtectionCustoms, the agency that has the final say on which products can cross the border, ultimately gave the green light to the entry of the modified Apple Watches, interpreting the redesign as having eliminated the initial infraction.
Following that approval, Apple gradually resumed the import and marketing of the updated models, while the underlying legal dispute with Masimo continued in various courts and administrative bodies.
Masimo's response and the legal battle on several fronts
Despite Customs validation and the ITC's favorable opinion regarding the redesigned watches, Massimo has not declared the conflict resolvedThe company has filed a specific lawsuit against the Customs Office, questioning the legality of the decision that allowed the re-importation of the new Apple Watch.
In addition to this route, Masimo maintains other lawsuits against Apple in federal courts from California. In one of them, he directly accuses the company of patent infringement and theft of trade secrets related to its medical monitoring technologies.
In this context, a federal jury granted Masimo $634 million in a patent lawsuit Held in November, the judgment was a significant sum that underscores the economic dimension of the dispute. Apple, for its part, has already announced that it will appeal the verdict and publicly maintained that most of Masimo's claims have been dismissed.
The technology company has maintained for years that Masimo's accusations are baseless and that it is a matter of a litigation campaign aimed at stifling competition in the connected health device market. According to Apple, dozens of lawsuits have been filed in the last six years, only a small fraction of which have been successful.
Meanwhile, Masimo is maintaining a more discreet profile in its public statements: a company spokesperson has opted to no comment in detail The latest resolutions, in a context where any statement may have an impact on ongoing proceedings.
A conflict with potential impact beyond the United States
Although the The Apple Watch import ban directly impacts the US marketThe consequences of this dispute are not limited to that country. What happens in the world's leading technology market can influence how regulators and courts act in other regions, including the European Union.
In Europe, Apple watches with blood oxygen measurement They have not been subjected to a similar blockadeHowever, EU regulators are closely monitoring patent disputes and potential abuses of dominant market position in the digital sphere. A firm decision against Apple in the United States could encourage further claims or investigations in Europe.
At the same time, this kind of dispute highlights the growing dependence on health technology manufacturers Regarding third-party patents, companies operating in Spain or other EU countries may face similar dilemmas if they integrate sensors or algorithms protected by patents from specialized companies.
For European consumers, the case serves as a reminder that Advanced health features are not guaranteed indefinitely. Changes in licenses, health regulations, or court rulings can force manufacturers to update, limit, or even remove certain features through simple software updates.
This type of situation can mean that, from one day to the next, a smartwatch stops offering exactly the same functions for which it was purchased, even though the hardware is perfectly capable of continuing to do so, something that has already been seen in other connected devices and platforms.
The role of large corporate transactions in the healthcare sector
Underlying this whole story is also the growing interest of large companies in the connected health sector. In February, the Danaher conglomerate reached a agreement to acquire Masimo for about $9.900 billion, an operation that reinforces the strategic value of its patents and medical technology.
With this purchase, Danaher would secure control of a key portfolio of innovations in non-invasive monitoring, with applications both in hospital environments and in the consumer market, where smartwatches and bracelets compete to offer increasingly accurate metrics.
For Apple, this move implies that, in the medium term, it may be facing not only a medium-sized, specialized company, but also... an industrial giant with ample resources to sustain prolonged litigation and negotiate licenses on terms more favorable to their own interests.
In Europe and Spain, where the connected health device market continues to gain traction, the strategic decisions made by companies like Apple, Masimo, or Danaher can change the availability of certain functions in consumer products, as well as the cost of licenses and agreements with hospitals, insurers or public health systems.
All of this places the dispute over the Apple Watch import ban In a broader context: the race to dominate the next generation of health monitoring tools, where access to the best patents can make all the difference.
The scenario emerging after the latest court decisions is one of a partial victory for Apple, which manages to keep its redesigned Apple Watch on the US market and avoid, for now, a new import ban, while Masimo continues to press the courts with parallel lawsuits and substantial damages at stake; pending a final ruling from the ITC and the appeals courts, the case remains open and demonstrates the extent to which the health functions of the devices we use daily depend on complex legal battles involving business interests, technological innovation, and the interpretation of patent laws.
